People

Yehezkel Ben-Ari

Yehezkel Ben-Ari, PhD

President, Acting Chief Executive Officer and Co-founder

Physiologist and biophysicist, Yehezkel Ben-Ari (YBA) has made many seminal discoveries on brain developmental sequences, infantile and adult epilepsies, the mechanisms of migration disorders and anoxic insults etc. These include the excitatory /inhibitory shift of GABA actions during brain development, the excitatory actions of GABA in epilepsies and other brain disorders, the formation of aberrant synapses in the epileptic brain, the maturation of neuronal and network activities and associated sequences. Author of 500 publications and amongst the highest quoted neuroscientists, Yehezkel Ben-Ari has received many prizes including the US and European Epilepsy research highest prizes and the INSERM 2009 Biomedical prize for his contributions to brain development. He has directed an INSERM unit for over 20 years, founded INMED and directed it since its foundation until September 2011.
Yehezkel Ben-Ari has recently suggested two major concepts including the “check point“ and “Neuroarcheology” concepts that suggest that neuronal activity controls the correct implementation of developmental sequences and a failed implementation of the program leads to delayed maturation of electrical properties of misplaced and misconnected neurons that in an adult brain will conserve immature features. This paves the way to novel therapeutic strategies based on the use of agents that specifically block immature channels and transporters. This strategy has been used successfully with our diuretic approach to treat ASD and epilepsies.



Denis Ravel

Denis Ravel, PhD

Chief Pharmaceutical Development Officer

Denis Ravel has more than 20 years of experience in the pharmaceutical and biotechnology industries. He began his career at Servier, a French pharmaceutical company, where he was successively responsible for pharmacology, preclinical and early clinical development (Phase I and II) of new molecules in the field of metabolic diseases. In 2001, he joined Genset / Merck-Serono, where he served, first as Director of Pharmaceutical Development at the Paris headquarters, and eventually as Director of the Research Center in San Diego, California. From 2003 to 2007 he was Chief R&D Officer at Diatos, a discovery company focusing on the development of new anticancer tumor targeting technologies.
In his more than 20 years career, he acquired extensive knowledge of preclinical and clinical development of biotech products as well as a deep experience in regulatory affairs in Europe in numerous therapeutic fields including CNS, metabolic diseases and cancer.
In 2007, Denis Ravel founded a consultant company (Initial R&D Consulting) assisting young biotech companies in preclinical and clinical development of biopharmaceuticals or small molecules.
Denis Ravel is an Engineer in Biology with a Ph.D. in Biochemistry from the University Pierre & Marie Curie (Paris).



Diana Ferrari

Diana Ferrari, PhD

Researcher and Project Manager

Diana Ferrari obtained her Ph.D. in Biochemistry and Molecular Biology from the University of Texas Medical Branch in Galveston (Texas) where she worked on the regulation of brain water homeostasis after neonatal insults such as hypoxia/ischemia. Her expertise on the development of the brain continued at INMED first under the supervision of C. Hammond, were she worked on the development of the dopaminergic neurons of the substantia nigra, and then with Y. Ben-Ari focusing on the development of electrical activities in different animal models of autism spectrum disorders. At Neurochlore, Diana is a researcher and the Project Manager responsible of the experimental design (together with YBA) and coordination of experiments, results and scientific reports.



Romain Nardou

Romain Nardou, PhD

Researcher

Romain Nardou obtained his PhD in Neuroscience from the Université de la Méditerranée Aix-Marseille 2 in Marseilles (France), where he worked on the role of the cation chloride cotransporters in the induction and expression of an epileptic focus in cortical immature structures.
During his PhD, he also determined, in an original model of neonatal epilepsy, the effect of the two mostly used antiepileptic drugs, diazepam and phenobarbital, that work on the GABAergic system.
At Neurochlore, Dr. Nardou is a researcher focusing notably on the chloride homeostasis and GABA function in different animal models of autism spectrum disorders.



Roman Tyzio

Roman Tyzio, PhD

Associate Researcher

Roman Tyzio is a Research Engineer at INMED (INSERM, U901). At Neurochlore, Roman is a researcher responsible for the electrophysiological study of the different models of autism. His research is focused on the role of excitatory and inhibitory receptors and their modulation in developmental and pathological processes.
Roman Tyzio obtained his Ph.D. in Physiology from Ivan Franko National University of Lviv (Ukraine). His professional interest is centred on the study of the physiological changes of neuronal functions, and, more particularly, on the development of GABAergic neurotransmission. Dr. Tyzio has expertise in various electrophysiological and imaging recordings from identified neurons in acute brain slices, slices in culture and transfected fluorescent cells.



Nail Burnashev

Nail Burnashev, PhD

Associate Researcher

Nail Burnashev is a Director of Research at INMED (INSERM U901). His current research is focused on understanding the basis of neuronal network dysfunctions associated with neurological disorders such as Tuberous Sclerosis Complex, epilepsies and autism, and finding the tools for targeted therapies. His research program is based on a multidisciplinary approach and involves intense collaborations with other research teams within INMED, and with several laboratories in France and abroad.
Dr. Burnashev has more than 20 years experience in neurophysiology focusing on synaptic functioning from the molecular (receptor) and individual synaptic level, to the level of neuronal networks. Dr. Burnashev received a Ph.D. from the All-Union Cardiology 
Research Center in Moscow, Russia, and a degree of Doctor of Science from the Bogomolets Institute for 
Physiology in Kiev, Ukraine.

 For more than a decade he worked as a Research Scientist at the Department of Cell Physiology (Max-Planck Institute for Medical Research, Heidelberg, Germany) headed by the Nobel Prize Winner Bert Sakmann. Prior to joining INMED, Dr. Burnashev, as a professor at the VU University Amsterdam, directed a team focused on the modulation of synaptic transmission, and network functioning associated with neurological disorders such as Alzheimer Disease and Fragile X syndrom. The results obtained have been published in leading international journals, and have become a groundwork in the field of structure-function relations of glutamate receptors.




Yehezkel Ben-Ari

Yehezkel Ben-Ari, PhD

President, Acting Chief executive Officer and Co-founder

Physiologist and biophysicist, Yehezkel Ben-Ari (YBA) has made many seminal discoveries on brain developmental sequences, infantile and adult epilepsies, the mechanisms of migration disorders and anoxic insults etc. These include the excitatory /inhibitory shift of GABA actions during brain development, the excitatory actions of GABA in epilepsies and other brain disorders, the formation of aberrant synapses in the epileptic brain, the maturation of neuronal and network activities and associated sequences. Author of 500 publications and amongst the highest quoted neuroscientists, Yehezkel Ben-Ari has received many prizes including the US and European Epilepsy research highest prizes and the INSERM 2009 Biomedical prize for his contributions to brain development. He has directed an INSERM unit for over 20 years, founded INMED and directed it since its foundation until September 2011.
Yehezkel Ben-Ari has recently suggested two major concepts including the “check point“ and “Neuroarcheology” concepts that suggest that neuronal activity controls the correct implementation of developmental sequences and a failed implementation of the program leads to delayed maturation of electrical properties of misplaced and misconnected neurons that in an adult brain will conserve immature features. This paves the way to novel therapeutic strategies based on the use of agents that specifically block immature channels and transporters. This strategy has been used successfully with our diuretic approach to treat ASD and epilepsies.



Eric Lemonnier

Eric Lemonnier, MD, PhD

Co-founder

Eric Lemonnier is a child and adolescent psychiatrist at the University Hospital in Brest, and is the head of the Research Center for Autism of Brittany. Dr. Lemonnier earned his Ph.D. in Paris in 1993 with the silver medal of the University of Port Royal, Paris, as well as his DEA in neuroscience. Before the opening of the Research Center for Autism of Brittany, to which he contributed to its creation, Dr. Lemmonier worked first as a psychiatrist at La Pitié-Salpêtrière in Paris, and then as a general child and adolescent psychiatrist at the University Hospital in Brest. Dr. Lemonnier created a national newspaper for doctors and doctors to be “Internes et chefs”.
Dr. Lemonnier has authored numerous publications in books and scientific journals, and has co-authored a patent with Dr. Y. Ben-Ari.



Nouchine Hadjikhani

Nouchine Hadjikhani, MD, PhD

Co-founder

Dr. Hadjikhani is an Associate Professor in Radiology at Harvard Medical School, and has more than 15 years of experience in brain imaging, with more than 50 publications in peer-reviewed journals.
She graduated from Medical School in Lausanne, Switzerland in 1992, and pursued her post-doctoral career at the Karolinska Institute in Sweden and then at the Martinos Center for Biomedical Imaging in Boston. She has been doing research on autism since 2000, using brain imaging and other behavioral measures such as eye-tracking. In 2006, she was the recipient of a Swiss National Science Foundation Professorship.



Dennis W. Choi

Dennis W. Choi, MD, PhD

Title

Dr. Dennis W. Choi



Andy Gyenes

Andy Gyenes, MS

Title

Andy Gyenes




› Pasko Rakic


Duberg Professor of Neurobiology and Neurology
Chairman, Department of Neurobiology, Yale University
Director, Kavli Institute of Neuroscience, Yale University

› David Amaral


Distinguished Professor
Department of Psychiatry and Behavioral Sciences
Director of Research, UC Davis MIND Institute

› Catherine Barthelemy, MD


Professeur des Universites, Praticien hospitalier
Universite Francois-Rabelais, Tours, France

› Rutger J. van der Gaag, MD


University Medical Centre Nijmegen St. Radboud, Department of Psychiatry, Nijmegen
University Centre for Child and Adolescent Psychiatry, Nijmegen, The Netherlands

› Patrick Bolton, MD


Professor of Child and Adolescent Psychiatry
King’s College London, University of London



Yehezkel Ben-Ari

Yehezkel Ben-Ari, PhD

President, Acting Chief Executive Officer and Co-founder

Physiologist and biophysicist, Yehezkel Ben-Ari (YBA) has made many seminal discoveries on brain developmental sequences, infantile and adult epilepsies, the mechanisms of migration disorders and anoxic insults etc. These include the excitatory /inhibitory shift of GABA actions during brain development, the excitatory actions of GABA in epilepsies and other brain disorders, the formation of aberrant synapses in the epileptic brain, the maturation of neuronal and network activities and associated sequences. Author of 500 publications and amongst the highest quoted neuroscientists, Yehezkel Ben-Ari has received many prizes including the US and European Epilepsy research highest prizes and the INSERM 2009 Biomedical prize for his contributions to brain development. He has directed an INSERM unit for over 20 years, founded INMED and directed it since its foundation until September 2011.
Yehezkel Ben-Ari has recently suggested two major concepts including the “check point“ and “Neuroarcheology” concepts that suggest that neuronal activity controls the correct implementation of developmental sequences and a failed implementation of the program leads to delayed maturation of electrical properties of misplaced and misconnected neurons that in an adult brain will conserve immature features. This paves the way to novel therapeutic strategies based on the use of agents that specifically block immature channels and transporters. This strategy has been used successfully with our diuretic approach to treat ASD and epilepsies.


Eric Lemonnier

› Eric Lemonnier, MD, PhD

Co-founder

Eric Lemonnier is a child and adolescent psychiatrist at the University Hospital in Brest, and is the head of the Research Center for Autism of Brittany. Dr. Lemonnier earned his Ph.D. in Paris in 1993 with the silver medal of the University of Port Royal, Paris, as well as his DEA in neuroscience. Before the opening of the Research Center for Autism of Brittany, to which he contributed to its creation, Dr. Lemmonier worked first as a psychiatrist at La Pitié-Salpêtrière in Paris, and then as a general child and adolescent psychiatrist at the University Hospital in Brest. Dr. Lemonnier created a national newspaper for doctors and doctors to be “Internes et chefs”.
Dr. Lemonnier has authored numerous publications in books and scientific journals, and has co-authored a patent with Dr. Y. Ben-Ari.


Nouchine Hadjikhani

› Nouchine Hadjikhani, MD, PhD

Co-founder

Dr. Hadjikhani is an Associate Professor in Radiology at Harvard Medical School, and has more than 15 years of experience in brain imaging, with more than 50 publications in peer-reviewed journals.
She graduated from Medical School in Lausanne, Switzerland in 1992, and pursued her post-doctoral career at the Karolinska Institute in Sweden and then at the Martinos Center for Biomedical Imaging in Boston. She has been doing research on autism since 2000, using brain imaging and other behavioral measures such as eye-tracking. In 2006, she was the recipient of a Swiss National Science Foundation Professorship.